Creative Medical Technology Holdings, Inc.

AI-generated fair value estimate for this company.

Method: Net-asset/net-cash value: $5.72M cash and cash equivalents less ~$0.01M total debt (net cash ~$5.71M) across 6.56M shares outstanding (~$0.87/share net-cash floor), plus a 15% premium for optionality on ongoing regenerative-medicine clinical programs (ImmCelz, AlloStem, CaverStem), giving ~$1.00/share.

Reasoning: Creative Medical Technology Holdings is a clinical-stage company with no material commercial revenue to discount, but it holds cash roughly equal to its entire market cap and minimal debt, so a net-cash-plus-pipeline-option approach is more grounded than a speculative DCF of unapproved therapies.